In vivo effects of scutellarin on the activities of CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 by cocktail probe drugs in rats

被引:6
|
作者
Lin, Zhiping [1 ]
Guo, Sixun [1 ]
Yang, Chunjuan [2 ]
Yu, Yue [1 ]
Xu, Lei [1 ]
Liu, Gaofeng [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Pharm, Harbin 150086, Peoples R China
[2] Harbin Med Univ, Coll Pharm, Harbin 150086, Peoples R China
来源
PHARMAZIE | 2014年 / 69卷 / 07期
基金
中国国家自然科学基金;
关键词
PHARMACOKINETICS; INHIBITION;
D O I
10.1691/ph.2014.3922
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: To investigate the influence of scutellarin on the activities of CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 in rats in vivo. Methods: Scutellarin and saline were intravenously administered to male Wistar rats via the caudal vein for 7 days consecutively. On the 8th day, the rats were treated with probe drugs of caffeine (10 mg/kg), tolbutamide (10 mg/kg), metoprolol (20 mg/kg), dapsone (10 mg/kg) by intraperitoneal injection, and the blood samples were collected at different times. The probe drugs in the blood samples were measured by ultra performance liquid chromatography mass spectrometer (UPLC-MS/MS) and the changes of the pharmacokinetics parameters of the drugs were observed to evaluate the effects of scutellarin on the four CYP450 isoforms in rats. Results: The activity of CYP1A2 in rats was inhibited significantly after treatment with scutellarin by increased caffeine t(1/2) (21.76%, P < 0.05), T-max (43.05%, P < 0.05), C-max (43.92%, P < 0.01) and AUC(0-infinity) (50.88%, P < 0.01) in the scutellarin-treated group compared with those of the blank control. The activity of CYP2C11 in rats was inhibited significantly after treatment with scutellarin by increased tolbutamide t(1/2) (16.74%, P < 0.01), T-max (116.87%, P < 0.05), C-max (63.78%, P < 0.01) and AUC(0-infinity) (70.61%, P < 0.01) in the scutellarin-treated group compared with those of the blank control. The activity of CYP3A1/2 in rats was inhibited significantly after treatment with scutellarin by increased dapsone t(1/2) (45.28%, P < 0.05), T-max (81.55%, P < 0.05), C-max (155.58%, P < 0.01) and AUC(0-infinity) (176.35%, P<0.01) in the scutellarin-treated group compared with those of the blank control. The pharmacokinetic parameters of metoprolol were not significantly changed in the scutellarin-treated group compared with those of the blank control. Conclusion: Scutellarin could significantly inhibit CYP1A2, CYP2C11 and CYP3A1/2 activities in rats in vivo, but had no effects on the activity of CYP2D1.
引用
收藏
页码:537 / 541
页数:5
相关论文
共 50 条
  • [21] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [22] Acute inflammation selectively downregulates the contents and activities of liver CYP2B1, CYP2C6, and CYP2C11 in rats
    Projean, D
    Dautrey, S
    Ducharme, J
    DRUG METABOLISM REVIEWS, 2003, 35 : 82 - 82
  • [23] An in vivo comparison of paroxetine and fluvoxamine: Effects on CYP1A2 and CYP2D6 activities.
    Ozdemir, V
    Naranjo, CA
    Shulman, RW
    Herrmann, N
    Sellers, EM
    Kalow, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII47 - PII47
  • [24] Inducibility of CYP1A2 by orneprazole in vivo related to the genetic polymorphism of CYP1A2
    Han, XM
    Ouyang, DS
    Chen, XP
    Shu, Y
    Jiang, CH
    Tan, ZR
    Zhou, HH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 540 - 543
  • [25] Effects of shuanghuanglian injection on the activities of CYP1A2, 2C11, 2D1 and 3A1/2 in rats in vivo and in vitro
    Shi, Yuan
    Xu, Juan
    Qiao, Yan
    Zhang, Wenlong
    Liu, Duo
    Qin, Mengnan
    Liu, Gaofeng
    Dong, Mei
    XENOBIOTICA, 2019, 49 (08) : 905 - 911
  • [26] Combined phenotypic assessment of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT2, and XO with the "Cooperstown 5+1 cocktail".
    Chainuvati, S
    Nafziger, AN
    Leeder, J
    Gaedigk, A
    Kearns, GL
    Sellers, E
    Zhang, Y
    Kashuba, AD
    Rowland, E
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P101 - P101
  • [27] Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4
    Madsen, H
    Rasmussen, BB
    Brosen, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (03) : 319 - 324
  • [28] Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities
    Mikstacka, Renata
    Baer-Dubowska, Wanda
    Wieczorek, Marcin
    Sobiak, Stanislaw
    MOLECULAR NUTRITION & FOOD RESEARCH, 2008, 52 : S77 - S83
  • [29] Assessment of the CYP1A2 & CYP2E1 activities in thalassemia patients
    Kukongviriyapan, V
    Somparn, N
    Senggunprai, L
    Kukongviriyapan, U
    Tassaneeyakul, W
    Jetsrisuparb, A
    FASEB JOURNAL, 2005, 19 (04): : A541 - A542
  • [30] 甲基莲心碱对大鼠肝CYP450酶含量及CYP2D1,CYP3A1,CYP2E1mRNA的影响
    刘萍
    黄颖
    胡本容
    王嘉陵
    向继洲
    中国实验方剂学杂志, 2010, 16 (10) : 161 - 164